CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
肿瘤免疫治疗的心血管毒性
英文原题：Cardiovascular toxicity of immune therapies for cancer.
查看英文原题
Cardiovascular toxicity of immune therapies for cancer.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
除传统放化疗和癌症靶向治疗外，免疫疗法（尤其免疫检查点抑制剂〔ICI〕和CAR-T 细胞疗法〔CAR-T〕）已在多种癌症中的应用呈指数级增加。与此同时，人们逐渐认识到免疫疗法可引起脱靶免疫相关不良事件，几乎影响任何器官系统，包括心血管系统。ICI 与心肌炎（发生率较低但病死率很高）、心包炎和心包积液、血管炎、血栓栓塞及潜在的加速动脉粥样硬化相关。CAR-T 引起全身细胞因子释放综合征时，也可能导致多种心血管后果，包括心律失常、心肌梗死和心力衰竭。本综述总结 ICI 和 CAR-T 相关心血管不良反应的现有认识。
展开英文摘要原文
In addition to conventional chemoradiation and targeted cancer therapy, the use of immune based therapies, specifically immune checkpoint inhibitors (ICIs) and chimeric antigen receptor T cell therapy (CAR-T), has increased exponentially across a wide spectrum of cancers. This has been paralleled by recognition of off-target immune related adverse events that can affect almost any organ system including the cardiovascular system.
The use of ICIs has been associated with myocarditis, a less common but highly fatal adverse effect, pericarditis and pericardial effusions, vasculitis, thromboembolism, and potentially accelerated atherosclerosis. CAR-T resulting in a systemic cytokine release syndrome has been associated with myriad cardiovascular consequences including arrhythmias, myocardial infarction, and heart failure. This review summarizes the current state of knowledge regarding adverse cardiovascular effects associated with ICIs and CAR-T.
论文信息
- 作者
- Palaskas NL、Ali HJ、Koutroumpakis E、Ganatra S、Deswal A
- 第一作者单位
- University of Texas MD Anderson Cancer Center, Houston, TX, USA.United States
- 通讯作者单位
- University of Texas MD Anderson Cancer Center, Houston, TX, USA 01805 adeswal@mdanderson.org.United States
- 文献类型
- 综述
- 期刊
- BMJ (Clinical research ed.)2024 May 15
- 原文标识
- PubMed 38749554 · DOI 10.1136/bmj-2023-075859